Scott A Armstrong

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Targeting epigenetic programs in MLL-rearranged leukemias
    Kathrin M Bernt
    Division of Hematology Oncology, Children s Hospital, Boston, MA 02215, USA
    Hematology Am Soc Hematol Educ Program 2011:354-60. 2011
  2. ncbi request reprint Molecular genetics of acute lymphoblastic leukemia
    Scott A Armstrong
    Children s Hospital, Karp Research Labs, Rm 08211, 1 Blackfan Circle, Boston, MA 02115, USA
    J Clin Oncol 23:6306-15. 2005
  3. pmc H3K79 methylation profiles define murine and human MLL-AF4 leukemias
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 14:355-68. 2008
  4. pmc MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L
    Kathrin M Bernt
    Division of Hematology Oncology, Children s Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 20:66-78. 2011
  5. pmc mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis
    Demetrios Kalaitzidis
    Division of Hematology Oncology, Children s Hospital Boston and Dana Farber Cancer Institute, Harvard Medical School and the Harvard Stem Cell Institute, Boston, MA 02115, USA
    Cell Stem Cell 11:429-39. 2012
  6. pmc Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML
    Florian H Heidel
    Division of Hematology Oncology, Children s Hospital, Boston, MA 02115, USA
    Cell Stem Cell 10:412-24. 2012
  7. pmc Polycomb repressive complex 2 is required for MLL-AF9 leukemia
    Tobias Neff
    Dana Farber Children s Hospital Cancer Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:5028-33. 2012
  8. pmc BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
    Victoria Del Gaizo Moore
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 111:2300-9. 2008
  9. pmc Chromatin-modifying enzymes as modulators of reprogramming
    Tamer T Onder
    Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Manton Center for Orphan Disease Research, Children s Hospital Boston and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 483:598-602. 2012
  10. pmc The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML
    Yingzi Wang
    Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 327:1650-3. 2010

Detail Information

Publications53

  1. doi request reprint Targeting epigenetic programs in MLL-rearranged leukemias
    Kathrin M Bernt
    Division of Hematology Oncology, Children s Hospital, Boston, MA 02215, USA
    Hematology Am Soc Hematol Educ Program 2011:354-60. 2011
    ..The clinical development of targeted inhibitors of these epigenetic regulators may therefore hold promise for the treatment of MLL-rearranged leukemia...
  2. ncbi request reprint Molecular genetics of acute lymphoblastic leukemia
    Scott A Armstrong
    Children s Hospital, Karp Research Labs, Rm 08211, 1 Blackfan Circle, Boston, MA 02115, USA
    J Clin Oncol 23:6306-15. 2005
    ....
  3. pmc H3K79 methylation profiles define murine and human MLL-AF4 leukemias
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 14:355-68. 2008
    ..We thus demonstrate that ectopic H3K79 methylation is a distinguishing feature of murine and human MLL-AF4 ALLs and is important for maintenance of MLL-AF4-driven gene expression...
  4. pmc MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L
    Kathrin M Bernt
    Division of Hematology Oncology, Children s Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 20:66-78. 2011
    ..Suppression of MLL translocation-associated gene expression corresponded with dependence of MLL-AF9 leukemia on Dot1l in vivo. These data point to DOT1L as a potential therapeutic target in MLL-rearranged leukemia...
  5. pmc mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis
    Demetrios Kalaitzidis
    Division of Hematology Oncology, Children s Hospital Boston and Dana Farber Cancer Institute, Harvard Medical School and the Harvard Stem Cell Institute, Boston, MA 02115, USA
    Cell Stem Cell 11:429-39. 2012
    ..These data delineate critical roles for mTORC1 in hematopoietic function and leukemogenesis and inform clinical strategies based on chronic mTORC1 inhibition...
  6. pmc Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML
    Florian H Heidel
    Division of Hematology Oncology, Children s Hospital, Boston, MA 02115, USA
    Cell Stem Cell 10:412-24. 2012
    ..In conclusion, inhibiting β-catenin by genetic inactivation or pharmacologic modulation is an effective combination therapy with imatinib and targets CML stem cells...
  7. pmc Polycomb repressive complex 2 is required for MLL-AF9 leukemia
    Tobias Neff
    Dana Farber Children s Hospital Cancer Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:5028-33. 2012
    ..Manipulating PRC2 function may be of therapeutic benefit in AML...
  8. pmc BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
    Victoria Del Gaizo Moore
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 111:2300-9. 2008
    ..The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies...
  9. pmc Chromatin-modifying enzymes as modulators of reprogramming
    Tamer T Onder
    Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Manton Center for Orphan Disease Research, Children s Hospital Boston and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 483:598-602. 2012
    ....
  10. pmc The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML
    Yingzi Wang
    Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 327:1650-3. 2010
    ..beta-catenin is not absolutely required for self-renewal of adult HSCs; thus, targeting the Wnt/beta-catenin pathway may represent a new therapeutic opportunity in AML...
  11. pmc Differential niche and Wnt requirements during acute myeloid leukemia progression
    Steven W Lane
    Division of Hematology Oncology, Children s Hospital Boston and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 118:2849-56. 2011
    ..These data identify differential engagement of HM associated with leukemic progression and identify an LSC niche that is physically distinct and independent of the constraints of Wnt signaling that apply to normal HSCs...
  12. ncbi request reprint MLL translocations, histone modifications and leukaemia stem-cell development
    Andrei V Krivtsov
    Division of Haematology Oncology, Children s Hospital, Department of Pediatric Oncology, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 7:823-33. 2007
    ..The link between a chromatin modulator and leukaemia stem cells provides support for epigenetic landscapes as an important part of leukaemia and normal stem-cell development...
  13. pmc DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions
    Li Lun Ho
    Department of Medical Oncology and Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Mol Cell Biol 33:1735-45. 2013
    ..Thus, H3K79 methylation is not essential for transcription of Wnt-responsive or other intestinal genes, and intestinal toxicity is not imperative when DOT1L is rendered inactive in vivo...
  14. ncbi request reprint MLL-rearranged leukemias: insights from gene expression profiling
    Scott A Armstrong
    Department of Pediatric Oncology, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Hematol 40:268-73. 2003
    ..Here we review insights gained from characterization of MLL-rearranged human leukemias by genome-wide expression profiling and compare these to data from model systems...
  15. pmc iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting
    Amit U Sinha
    Division of Hematology Oncology, Department of Pediatric Oncology, Dana Farber Cancer Institute, Children s Hospital Boston and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e31690. 2012
    ..We illustrate the power of iCanPlot by showing an example of how it can be used to interpret histone modifications in the context of gene expression...
  16. pmc Gene expression profiling of leukemia stem cells
    Andrei V Krivtsov
    Department of Pediatric Oncology, Division of Hematology Oncology, Children s Hospital, Dana Farber Cancer Insitute, Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 538:231-46. 2009
    ..Here we describe methods to isolate a leukemia stem cell population, amplify RNA, and perform microarray analyses...
  17. ncbi request reprint FLT3 as a therapeutic target in childhood acute leukemia
    Matthew C Stubbs
    Division of Hematology Oncology, Children s Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Curr Drug Targets 8:703-14. 2007
    ..We will examine the successes in elucidating FLT3 function in acute leukemias, highlight current FLT3 targeted therapeutics, and discuss how FLT3 inhibitors might be used in combination therapies in the future...
  18. pmc HOXA9 is required for survival in human MLL-rearranged acute leukemias
    Joerg Faber
    Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Blood 113:2375-85. 2009
    ..Our data indicate an important role for HOXA9 in human MLL-rearranged leukemias and suggest that targeting HOXA9 or downstream programs may be a novel therapeutic option...
  19. ncbi request reprint Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
    Guo Wei
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 10:331-42. 2006
    ..Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer...
  20. pmc Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
    Aniruddha J Deshpande
    Division of Hematology Oncology, Children s Hospital, Boston, MA, USA
    Blood 121:2533-41. 2013
    ..These results indicate that patients bearing the t(6;11)(q27;q23) translocation may benefit from therapeutic agents targeting aberrant H3K79 methylation...
  21. pmc MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1
    Przemyslaw Juszczynski
    Department of Medical Oncology, Dana Farber Cancer Institute Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Clin Cancer Res 16:2122-30. 2010
    ..We analyzed molecular markers of MLL rearrangement for use in rapid diagnostic assays and found the immunomodulatory protein, Galectin-1 (Gal-1), to be selectively expressed in MLL-rearranged B-ALL...
  22. ncbi request reprint Therapeutic implications of leukemia stem cell development
    Matthew C Stubbs
    Division of Hematology Oncology, Children s Hospital Boston, Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 13:3439-42. 2007
    ..The perturbed developmental pathways and cellular context of LSC development have implications for the development of new therapeutic approaches...
  23. doi request reprint Transformation from committed progenitor to leukemia stem cells
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02215, USA
    Ann N Y Acad Sci 1176:144-9. 2009
    ....
  24. pmc Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains
    Jennifer J Trowbridge
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Division of Hematology Oncology, Children s Hospital Boston, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 26:344-9. 2012
    ..These results suggest that LSCs depend on not only active expression of leukemogenic programs, but also DNA methylation-mediated silencing of bivalent domains to enforce transcriptional repression...
  25. ncbi request reprint Mixed lineage leukemia translocations and a leukemia stem cell program
    Joerg Faber
    Division of Hematology Oncology, Children s Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 67:8425-8. 2007
    ..The findings suggest a basis to understand the pathobiology of CSC and possible strategies to attack them to undermine the self-renewal capacity of a tumor...
  26. pmc The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
    Florian H Heidel
    Division of Hematology Oncology, Boston Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 210:15-22. 2013
    ..Thus, inactivation of Llgl1 enhances HSC self-renewal and fitness and is associated with unfavorable outcome in human AML...
  27. doi request reprint Linking miRNA regulation to BCR-ABL expression: the next dimension
    Jörg Faber
    Division of Hematology Oncology, Children s Hospital Boston, Department of Pediatric Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 13:467-9. 2008
    ..These findings may have broad implications for mechanisms underlying malignant transformation in hematopoietic and other malignancies...
  28. doi request reprint Cancer: inappropriate expression of stem cell programs?
    Yingzi Wang
    Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cell Stem Cell 2:297-9. 2008
    ..In this issue of Cell Stem Cell, Wong et al. (2008) define a core embryonic stem cell (ESC)-like gene expression program that may be important for CSC function in multiple epithelial cancers...
  29. ncbi request reprint FLT3 mutations in childhood acute lymphoblastic leukemia
    Scott A Armstrong
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 103:3544-6. 2004
    ..These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors...
  30. ncbi request reprint FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress
    Zuzana Tothova
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, and Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
    Cell 128:325-39. 2007
    ..Thus, FoxO proteins play essential roles in the response to physiologic oxidative stress and thereby mediate quiescence and enhanced survival in the HSC compartment, a function that is required for its long-term regenerative potential...
  31. pmc eXframe: reusable framework for storage, analysis and visualization of genomics experiments
    Amit U Sinha
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BMC Bioinformatics 12:452. 2011
    ..Moreover, many of them are tailored for a single type of technology or measurement and do not support the integration of multiple data types...
  32. pmc AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias
    Stephen M Sykes
    Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Cell 146:697-708. 2011
    ..These data reveal a molecular role for AKT/FOXO and JNK/c-JUN in maintaining a differentiation blockade that can be targeted to inhibit leukemias with a range of genetic lesions...
  33. pmc Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis
    Inga Hofmann
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cell Stem Cell 4:559-67. 2009
    ..Furthermore, the Hh pathway may not be a compelling target in certain hematopoietic malignancies...
  34. ncbi request reprint Microarrays to identify new therapeutic strategies for cancer
    Christopher Sears
    Division of Hematology Oncology, Children s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Adv Cancer Res 96:51-74. 2007
    ..This chapter will provide examples where microarray analysis has been used in an attempt to either direct the use of current therapies or identify new potential therapeutic avenues...
  35. ncbi request reprint Genome-wide SNP analysis in cancer: leukemia shows the way
    Yingzi Wang
    Division of Hematology Oncology, Children s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 11:308-9. 2007
    ..These studies not only provide information about the multistep development of leukemia, but also demonstrate the potential for this approach in other cancers...
  36. ncbi request reprint Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital, Boston, Massachusetts 02115, USA
    Nature 442:818-22. 2006
    ..Our findings define progression from normal progenitor to cancer stem cell, and suggest that targeting a self-renewal programme expressed in an abnormal context may be possible...
  37. doi request reprint Chromatin modifications as therapeutic targets in MLL-rearranged leukemia
    Aniruddha J Deshpande
    Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Trends Immunol 33:563-70. 2012
    ..These studies may lead to the advent of a new generation of much-needed therapeutic modalities in leukemia and other cancers...
  38. pmc Self-renewal related signaling in myeloid leukemia stem cells
    Florian H Heidel
    Division of Hematology Oncology, Children s Hospital, Boston, MA, USA
    Int J Hematol 94:109-17. 2011
    ..Here we will focus on self-renewal related signaling in myeloid leukemia stem cells and its therapeutic relevance...
  39. ncbi request reprint Comparison of human genomics and genetic models of cancer to identify novel therapeutic targets
    Scott A Armstrong
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School and Howard Hughes Medical Institute, Boston, MA 02115, USA
    Cell Cycle 2:408-9. 2003
  40. ncbi request reprint High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention...
  41. ncbi request reprint Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
    Michael Certo
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Cancer Cell 9:351-65. 2006
    ..Our data allow us to distinguish a cellular state we call "primed for death," which can be determined by BH3 profiling and which correlates with dependence on antiapoptotic family members for survival...
  42. pmc Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
    Ann Mullally
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 121:3692-702. 2013
    ....
  43. ncbi request reprint Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation
    Adolfo A Ferrando
    Department of Pediatric Oncology, Mayer 630, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 102:262-8. 2003
    ..Our findings implicate dysregulation of HOX gene family members as a dominant mechanism of leukemic transformation induced by chimeric MLL oncogenes...
  44. pmc Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease
    Jing Wang
    Department of Pathology and Medicine, Howard Hughes Medical Institute, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    EMBO J 24:368-81. 2005
    ..This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations...
  45. ncbi request reprint Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia
    Sara Maia
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:10050-8. 2005
    ..This study suggests that (a) BAX-delta may serve as a widely expressed TAA in B-ALL and (b) gene expression profiling can be a generalizable tool to identify immunologic targets for cancer immunotherapy...
  46. doi request reprint Leukemia stem cells and human acute lymphoblastic leukemia
    Kathrin M Bernt
    Division of Hematology Oncology, Children s Hospital, and Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Hematol 46:33-8. 2009
    ..In common childhood ALL, current evidence points towards the cell of origin being a committed lymphoid progenitor. In this review, we highlight recent findings relating to the question of leukemia stem cells in ALL...
  47. pmc In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling
    Peter G Miller
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 24:45-58. 2013
    ..Our results establish the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML. ..
  48. pmc The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons
    Shannan J Ho Sui
    Department of Biostatistics, HSPH Bioinformatics Core, Harvard School of Public Health, Boston, MA, USA
    Nucleic Acids Res 40:D984-91. 2012
    ..The SCDE is available at http://discovery.hsci.harvard.edu...
  49. ncbi request reprint MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    Scott A Armstrong
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 30:41-7. 2002
    ..Establishing that MLL is a unique entity is critical, as it mandates the examination of selectively expressed genes for urgently needed molecular targets...
  50. ncbi request reprint Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification
    Scott A Armstrong
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 3:173-83. 2003
    ..Finally, we developed a mouse model of MLL and used bioluminescent imaging to determine that PKC412 is active against MLL in vivo...
  51. ncbi request reprint Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias
    Scott A Armstrong
    Department of Pathology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Hematol 9:339-44. 2002
    ..This technology is beginning to be applied to the study of human leukemias. Recent studies focusing on lymphoblastic leukemia have provided insight into classification and pathogenesis...
  52. ncbi request reprint The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease
    Justin Lamb
    Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
    Science 313:1929-35. 2006
    ..These results indicate the feasibility of the approach and suggest the value of a large-scale community Connectivity Map project...
  53. ncbi request reprint Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells
    Wim J E Tissing
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 109:3929-35. 2007
    ..Biologic characterization of these genes and pathways might elucidate the action of glucocorticoids in ALL cells, possibly suggesting causes of glucocorticoid resistance and new potential targets for therapy...